Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails

Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test.

The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN. The Retrophin (NASDAQ: RTRX) drug flunked all of its main and secondary goals in the study, which tested fosmetpantotenate against a placebo in PKAN patients.